SEC Filings

Form 10-Q
DURECT CORP filed this Form 10-Q on 11/08/2018
Document Outline
Entire Document (5633.3 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - INDEX
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - DURECT CORPORATION
Page 5 - DURECT CORPORATION
Page 6 - DURECT CORPORATION
Page 7 - Revenue Recognition
Page 8 - Licenses of intellectual property:
Page 9 - Revenue Revenue from Contract with Customers
Page 10 - Net Income (Loss) Per Share
Page 11 - Compensation Stock Compensation (Topic 718)
Page 12 - Agreement with Sandoz AG
Page 13 - Agreement with Pain Therapeutics, Inc.
Page 14 - Note 3. Financial Instruments
Page 15 - N/A
Page 16 - Note 4. Stock-Based Compensation
Page 17 - Note 6. Commitments
Page 18 - Note 7. Stockholders Equity
Page 19 - Forward-looking statements made in this report include, for example, statements about:
Page 20 - Forward-looking statements are not guarantees of future performance and involve risks and uncertaint
Page 21 - Chronic Metabolic Disease Program with Orally Administered DUR-928
Page 22 - Acute Organ Injury Program with Injectable DUR-928
Page 23 - Skin Inflammatory Disorder Program with Topical DUR-928
Page 24 - PERSERIS (risperidone)
Page 25 - Other Programs
Page 26 - Product revenue
Page 27 - Research and development
Page 28 - Depot injectable programs
Page 29 - Other income (expense).
Page 30 - Contractual Obligations and Commitments
Page 31 - Item 3.ive Disclosures about Market Risk
Page 32 - PART II OTHER INFORMATION
Page 33 - If we experience delays or difficulties in the enrollment of subjects in clinical trials, our produc
Page 34 - The path to regulatory approval of DUR-928 is uncertain.
Page 35 - We do not control development or commercialization of PERSERIS
Page 36 - Development of our pharmaceutical product candidates is not complete, and we cannot be certain that
Page 37 - N/A
Page 38 - Certain of our drug candidates that may be developed, including REMOXY ER, are subject to mandatory
Page 39 - We depend to a large extent on third-party collaborators, and we have limited or no control over the
Page 40 - Our cash flows are likely to differ from our reported revenues
Page 41 - Failure to comply with ongoing governmental regulations for our pharmaceutical product candidates co
Page 42 - We have a history of operating losses, expect to continue to have losses in the future and may never
Page 43 - We rely heavily on third parties to support development, clinical testing and manufacturing of our p
Page 44 - Myriad GeneticsMyriad GeneticsMyriad Genetics
Page 45 - MedImmune v. Genentech
Page 46 - Write-offs related to the impairment of our goodwill, long-lived assets, inventories and other non-c
Page 47 - We may not successfully manage our company through varying business cycles
Page 48 - Risks Related To Our Industry
Page 49 - Our relationships with customers and third-party payers will be subject to applicable anti-kickback,
Page 50 - Healthcare reform measures could hinder or prevent our product candidates commercial success.
Page 51 - We could be exposed to significant product liability claims which could be time consuming and costly
Page 52 - If users of our products are unable to obtain adequate reimbursement from third-party payers, or if
Page 53 - Risks Related To Our Common Stock
Page 54 - The price of our common stock may be volatile
Page 55 - We have broad discretion over the use of our cash and investments, and their investment may not alwa
Page 56 - N/A
Page 57 - SIGNATURES
Subdocument 2 - EX-10.3 - EX-10.3
Page 1 - Exhibit 10.3
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - e.g.
Page 7 - N/A
Page 8 - N/A
Page 9 - III. PAYMENT PROVISIONS
Page 10 - Wall Street Journal
Page 11 - N/A
Page 12 - N/A
Page 13 - V. REPORTING OBLIGATIONS
Page 14 - VI. INFRINGEMENT
Page 15 - N/A
Page 16 - VII
Page 17 - N/A
Page 18 - VIII. SUBLICENSE(S)
Page 19 - IX. MISCELLANEOUS
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - AGREED AND ACCEPTED:
Page 28 - APPENDIX A
Page 29 - N/A
Page 30 - Proprietary Information
Page 31 - N/A
Page 32 - N/A
Page 33 - APPENDIX C
Subdocument 3 - EX-10.4 - EX-10.4
Page 1 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 2 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 3 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 4 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 5 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Subdocument 4 - EX-10.5 - EX-10.5
Page 1 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 2 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 3 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 4 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 5 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 6 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Page 7 - Confidential treatment has been sought for portions of this agreement. The copy filed herewithin omi
Subdocument 5 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 6 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 7 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 8 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer